Impact of Glycosylation on Effector Functions of Therapeutic IgG †
نویسندگان
چکیده
Human IgG has only one conserved glycosylation site located in the Cγ2 domain of the Fc region that accounts for the presence of two sugar moieties per IgG. These IgG sugar cores play a critical role in a number of IgG effector functions. In the present review, we describe the main characteristics of IgG Fc glycosylation and some abnormalities of serum IgG glycosylation. We also discuss how glycosylation impacts on monoclonal antibodies (mAbs) and IVIg effector functions and how these molecules can be engineered. Several therapeutic antibodies have now been engineered to be no- or low-fucose antibodies and are currently tested in clinical trials. They exhibit an increased binding to activating FcγRIIIA and trigger a strong antibody-dependent cell cytotoxicity (ADCC) as compared to their highly-fucosylated counterparts. They represent a new generation of therapeutic antibodies that are likely to show a better clinical efficacy in patients, notably in cancer patients where cytotoxic antibodies are needed.
منابع مشابه
In Response to: ‘Impact of Glycosylation on Effector Functions of Therapeutic IgG’ (Pharmaceuticals 2010, 3, 146–157)
To complete the review article by Abes and colleagues (Pharmaceuticals 2010, 3, 146-157) which provides a good overview on recently developed approaches for generation of glyco-modified antibodies and the impact of glyco-modification of antibodies on their effector functions, important information should be added, namely that - besides the Glycart and the Biowa approach to generate de-fucosylat...
متن کاملGlycosylation Variations with Expression Systems and Their Impact on Biological Activity of Therapeutic Immunoglobulins
soluble serum glycoproteins involved in the defense mechanism of the immune system. IgGs are the major components of the five different classes of immunoglobulins (namely IgA, IgD, IgE, IgG, and IgM; Figure 1 provides a schematic representation) (1). The serum concentration of IgG is up to 13.5 mg/mL (Figure 1). The four isotypes of IgGs are classified as IgG1, IgG2, IgG3 and IgG4 (Figure 2). T...
متن کاملMulti-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants
Therapeutic performance of recombinant antibodies relies on two independent mechanisms: antigen recognition and Fc-mediated antibody effector functions. Interaction of Fc-fragment with different FcR triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity and determines longevity of the antibody in serum. In context of therapeutic antibodies FcγRs play the most im...
متن کاملCrystallizable Fragment Glycoengineering for Therapeutic Antibodies Development
Monoclonal antibody (mAb)-based therapeutics are the fastest growing class of human pharmaceuticals. They are typically IgG1 molecules with N-glycans attached to the N297 residue on crystallizable fragment (Fc). Different Fc glycoforms impact their effector function, pharmacokinetics, stability, aggregation, safety, and immunogenicity. Fc glycoforms affect mAbs effector functions including anti...
متن کاملSignificant Impact of Single N-Glycan Residues on the Biological Activity of Fc-based Antibody-like Fragments*
Recent studies have demonstrated that IgG-Fc fragments (Fcabs) can be engineered to form antigen-binding sites with antibody properties. Thus they may serve as an attractive alternative to conventional antibodies in therapeutic applications. The critical influence of Fc glycosylation on effector functions of IgGs is well documented; however, whether this applies to Fcabs is not known. Here we u...
متن کامل